-
2020 Oncology New Drug Data Card-Inituzumab
Time of Update: 2021-03-24
The data show that initumumab combined with vinorelbine In the treatment of HER2-positive metastatic breast cancer patients who have received one or more chemotherapy regimens in the past, compared with vinorelbine can significantly prolong the median PFS of the primary endpoint (39.
-
The new version of the medical insurance catalog is launched, and 119 drugs can be reimbursed from March 1st
Time of Update: 2021-03-24
" said Nie Guangmeng, director of the medical insurance office of Beijing Tsinghua Chang Gung Memorial Hospital, in order to let patients enjoy The latest medical insurance reimbursement policy, the hospital pharmnet.
-
The clinical application of Boan Bio-Navulumab injection was accepted
Time of Update: 2021-03-24
Tumor immunotherapy represented by PD-1 inhibitors has become one of the main methods of cancer treatment in China and even globally.
As the world's first PD-1 immune checkpoint inhibitor approved by regulatory agencies, nivolumab injection has become an important choice for the treatment of a variety of tumors, and has been approved for more than a dozen indications worldwide.
-
The 2020 transcripts of 241 pharmaceutical companies are released!
Time of Update: 2021-03-24
Regarding the substantial growth in performance, Yiling Pharmaceutical said that on the one hand, the brand awareness of the company's Lianhua Qingwen products has been greatly improved, the domestic market demand has increased significantly, and sales have also been achieved in more than ten registered overseas countries.
-
National Health and Wellness Commission: disposable medical supplies or was transferred out of the catalog!
Time of Update: 2021-03-24
For those that cannot be reused, they should try their best to choose corresponding alternative products or materials to avoid setting unreasonable technical barriers; The second is to cooperate with the drug regulatory department to strengthen research and demonstration, and to support the reuse of clinical norms that can be reused in the diagnosis and treatment process and can be guaranteed to be safe and effective, not included in the catalog of single-use medical devices.
-
From now on, 119 new drugs will be reimbursable for health insurance
Time of Update: 2021-03-24
At the same time, for drugs successfully negotiated by the state, for long-term outpatient treatment, high cost, and suitable for the treatment of various diseases, in order to further reduce the burden of medical expenses of the masses and facilitate the outpatient treatment of the masses, this city refers to the medical insurance outpatient clinics for urban employees and urban and rural residents.
-
AstraZeneca withdraws U.S. eligibility for imfinzi bladder cancer indication
Time of Update: 2021-03-24
At that time, there was an analysis that the FDA may re-examine Imfinzi's previous accelerated approval for the second-line indication of bladder cancer.
-
Global oncology drug giants ranked TOP10 in 2020
Time of Update: 2021-03-24
Tyvyt (sintilimab), which cooperates with Cinda, helps Lilly occupy a place in the field of tumor immunotherapy, achieving revenue of 309 million US dollars in 2020; LOXO Oncology, which has been heavily acquired, begins In return, Retevmo (RET inhibitor) gained US$37 million in half a year from the market, and the BTK C481S inhibitor LOXO-305 has also been advanced to phase III clinical trials, which is only one step away from the market.
-
From today, the implementation of 4 regulations affects all pharmaceutical workers
Time of Update: 2021-03-24
From March 1st, the supplementary provisions of the new criminal law, the 2020 drug catalogue, the management methods for the batch issuance of biological products, and the management methods for the clinical application of anti-tumor drugs have been implemented, affecting all pharmaceutical workers.
-
Interpretation | What should I do if there is a change in a listed Chinese medicine?
Time of Update: 2021-03-24
(6) The revised drug label sample draft with detailed revision instructions(7) Pharmaceutical research materialsCarry out research in accordance with the relevant technical guidelines for changes in the pharmacy of listed traditional Chinese medicines published by the National Drug Administration, and provide part or all of the pharmacy research and test data and necessary original registration applications according to the specific requirements of the relevant technical guidelines for various changes.
-
Yuandong's new injection products are coming!
Time of Update: 2021-03-24
Figure 1: Registration status of Yuandong's Phenylephrine Hydrochloride Injection Source: CDE official website Figure 2: Overall sales of phenylephrine hydrochloride injection Source: Comprehensive compilation of Minet's database At present, only Shanghai Hefeng Pharmaceutical has obtained approval for phenylephrine hydrochloride injection on the domestic market, and no company has reviewed it yet .
-
Kangfang Bio/Zhengda Tianqing PD-1 first-line squamous NSCLC phase III clinical trial reached the primary endpoint
Time of Update: 2021-03-24
On February 24, Kangfang Biological and Sino Biopharmaceutical jointly announced that their jointly developed anti-PD-1 monoclonal antibody "Paimrizumab" combined with chemotherapy for the first-line treatment of advanced/metastatic squamous non-small cell lung cancer (NSCLC) The phase III clinical interim analysis reached the main research endpoint, and plans to communicate with CDE to submit the listing application.
-
Multinational pharmaceutical companies 2020 China performance PK! Bayer, Sanofi!
Time of Update: 2021-03-24
Under the influence of many factors such as the new crown epidemic, mass procurement, and medical insurance negotiations, the performance of multinational pharmaceutical companies in China has clearly differentiated.
-
2021 Central No. 1 Document Released, Village-level Medical Services Ushered in a Big Change
Time of Update: 2021-03-24
The document proposes to comprehensively promote the construction of healthy villages, improve the standardization of village clinics and the level of health management, promote the transformation of rural doctors into practicing (assistant) doctors, and improve the level of grassroots health services by means of stationing and patrolling.
-
Merck and Day One collaborate to develop MEK inhibitor Pimasertib
Time of Update: 2021-03-24
Day One plans to further advance the Phase 1/2 study of the drug to evaluate the safety of Pimasertib in combination with DAY101 for the treatment of patients ≥12 years of age with relapsed, progressive or refractory solid tumors and abnormal MAPK pathway , Tolerability and preliminary efficacy.
-
China urgently needs new drugs for overseas rare diseases: more than 10 models have been approved and multiple models have been submitted for marketing applications
Time of Update: 2021-03-24
Source: Guanlan PharmaceuticalClinically urgently needed overseas new drugs mainly refer to those that have been marketed in Europe, America and Japan in recent years but have not yet been marketed in China, and are used to treat rare diseases, severely life-threatening or severely affecting the quality of life, and there are no effective treatments or obvious clinical advantages.
-
INOVIO announces the administration of the first subject of Lassa fever vaccine
Time of Update: 2021-03-24
INOVIO announced today that the Phase 1B clinical trial of INO-4500 (its Lassa fever DNA vaccine candidate) in Ghana has completed the first subject administration.
-
Which varieties of proprietary Chinese medicines have been signaled or will be included first?
Time of Update: 2021-03-24
Medical Network News, February 24th, the signal of centralized procurement of Chinese patent medicines has come out. Which varieties may be included first? Popular varieties of Chinese patent medic
-
Xianju Pharmaceutical: Received notification of acceptance of consistency evaluation of prednisone acetate tablets
Time of Update: 2021-03-24
They are commonly used, safe and effective drugs for the treatment of allergic and autoimmune inflammatory diseases.
The current product implementation standard is "Chinese Pharmacopoeia" 2020 edition two.
-
Yuandong Bio-Caffeine Citrate Injection Passes the Consistency Evaluation of Injection Quality and Efficacy
Time of Update: 2021-03-24
On April 19, 2019, the application for consistency evaluation of caffeine citrate injection submitted by the company to the State Food and Drug Administration was accepted.
